Enterically coated cysteamine, cystamine and derivatives thereof
AssigneeThe Regents of the University of California
InventorsRanjan Dohil, Jerry Schneider
Life of this patent
Estimating the term…
Abstract
The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
Claims20
A composition comprising:
- a tablet or capsule containing a core of cysteamine bitartrate and cystamine or a pharmaceutically-acceptable salt thereof, mixed with one or more pharmaceutically-acceptable binders;
- and
- an enteric coating which encases the core, wherein the enteric coating begins to dissolve in an aqueous solution at a pH between about 4.5 to about 5.5, and
- wherein the tablet or capsule comprises a total weight of approximately 100 mg to 1000 mg.
A dosage form comprising:
- a capsule containing granules having a core comprising cysteamine bitartrate and cystamine or a pharmaceutically-acceptable salt thereof;
- at least one pharmaceutically acceptable binder;
- and
- an enteric coating surrounding the core, wherein the enterically-coated granules release cysteamine and cystamine or a pharmaceutically-acceptable salt thereof at a pH of 4.5-6.5, and
- wherein the capsule has a total weight of approximately 100 mg to 1000 mg.
Enterically-coated granules of cysteamine bitartrate and cystamine or a pharmaceutically-acceptable salt thereof, mixed with one or more pharmaceutically-acceptable binders, wherein the enterically coated granules are compressed in the form of a tablet or are loaded into a capsule, wherein the tablet or capsule has a total weight of about 100 mg to 1000 mg and wherein the enteric coating begins to dissolve in an aqueous solution at a pH between about 4.5 to about 5.5.
A composition comprising:
- a capsule filled with a plurality of enterically coated cysteamine bitartrate and cystamine granules, mixed with one or more pharmaceutically-acceptable binders,
- wherein the enteric coating of the plurality of granules is of a thickness that begins to dissolve in an aqueous solution at a pH between about 4.5 to about 5.5 and releases cysteamine bitartrate and cystamine over a period of about 2-3 hours, and
- wherein the capsule comprises a total weight of approximately 100 mg to 1000 mg.
Dependencies are inferred from the claim text.